A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins

Peter J. Bredenbeek, Richard Molenkamp, Willy J.M. Spaan, Vincent Deubel, Phillippe Marianneau, Maria S. Salvato, Dmitry Moshkoff, Juan Zapata, Ilia Tikhonov, Jean Patterson, Ricardo Carrion, Anysha Ticer, Kathleen Brasky, Igor S. Lukashevich

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


The Yellow Fever Vaccine 17D (YFV17D) has been used as a vector for the Lassa virus glycoprotein precursor (LASV-GPC) resulting in construction of YFV17D/LASV-GPC recombinant virus. The virus was replication-competent and processed the LASV-GPC in cell cultures. The recombinant replicated poorly in guinea pigs but still elicited specific antibodies against LASV and YFV17D antigens. A single subcutaneous injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. This study demonstrates the potential to develop an YFV17D-based bivalent vaccine against two viruses that are endemic in the same area of Africa.

Original languageEnglish (US)
Pages (from-to)299-304
Number of pages6
Issue number2
StatePublished - Feb 20 2006
Externally publishedYes


  • Recombinant vaccine
  • YFV17D vaccine
  • Yellow and Lassa Fevers

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins'. Together they form a unique fingerprint.

Cite this